LUNG Share Price | Pulmonx Corp. Stock Analysis & Recommendation

Q: What does Pulmonx Corp. do?

Overview:Pulmonx Corporation is a commercial-stage medical technology company focused on providing planning tools and treatments for obstructive lung disease within the Pharmaceuticals & Biotechnology industry.Financial Snapshot:Most recent Net Sales: 23 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) Market-cap: USD 109.10 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.65 Return on Equity: -71.30% Price to Book: 1.40Contact Details:Address: 700 Chesapeake Dr, REDWOOD CITY CA: 94063 Tel: 1 650 3640400 Fax: 1 302 6555049

Q: Should I buy, sell or hold Pulmonx Corp.?

Based on the current situation of Pulmonx Corp., it would be advisable to hold your position rather than buy or sell at this time. The company has shown flat results recently, with a notably low return on capital employed (ROCE) of -60.68% and a high debt-equity ratio of -41.21%. Additionally, the operating profit is negative at USD -14.29, indicating ongoing financial challenges.The stock also appears risky, with negative EBITDA and trading at levels that are concerning compared to its historical valuations. While it has generated a 0% return over the past year, profits have increased by 5.7%, which suggests some potential for improvement, but not enough to warrant a buy.On a positive note, the high institutional holdings at 100% indicate that sophisticated investors are backing the company, which could provide some level of confidence in its future prospects. However, given the current financial metrics and risks involved, holding your investment seems to be the most prudent choice for now.

Q: Is Pulmonx Corp. technically bullish or bearish?

As of 26 August 2025, the technical trend for Pulmonx Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearishness and the weekly KST and OBV also showing bearish signals. However, the weekly MACD and RSI are mildly bullish and bullish respectively, suggesting some positive momentum. The Bollinger Bands are bearish on both weekly and monthly time frames. In terms of performance, Pulmonx Corp. has significantly underperformed against the S&P 500, with a year-to-date return of -76.44% compared to the S&P 500's 12.22%, and a one-year return of -80.95% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

841.85 k

Shareholding (Dec 2025)

FII

14.27%

Held by 66 FIIs

DII

41.9%

Held by 43 DIIs

Promoter

4.91%

How big is Pulmonx Corp.?

22-Jun-2025

As of Jun 18, Pulmonx Corp. has a market capitalization of 109.10 million, with net sales of 87.48 million and a net profit of -57.10 million over the last four quarters. Shareholder's funds are reported at 85.81 million, and total assets amount to 167.71 million.

View full answer

What does Pulmonx Corp. do?

22-Jun-2025

Pulmonx Corporation is a medical technology company specializing in treatments for obstructive lung disease, with recent net sales of $23 million and a net loss of $14 million. It has a market cap of $109.10 million and key metrics indicating it is currently loss-making.

View full answer

Should I buy, sell or hold Pulmonx Corp.?

22-Jun-2025

Who are in the management team of Pulmonx Corp.?

22-Jun-2025

As of March 2022, the management team of Pulmonx Corp. includes Chairman Dana Mead, President and CEO Glendon French, and Directors Thomas Burns and Georgia Garinois-Melenikiotou.

View full answer

Is Pulmonx Corp. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Pulmonx Corp. shows a mildly bearish trend with mixed signals from technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -76.44% compared to the S&P's 12.22%.

View full answer

Compare Pulmonx Corp. with Similar Stocks

Nano-X Imaging Ltd.Organogenesis Holdings, Inc.AirSculpt Technologies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Flat results in Sep 25

ROCE(HY) Lowest at -73.73%
DEBT-EQUITY RATIO (HY) Highest at -33.72 %

Risky -

High Institutional Holdings at 100%

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 68 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.64

Return on Equity

-94.54%

Price to Book

1.13

Revenue and Profits:

Net Sales:

23 Million

(Quarterly Results - Dec 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-47.3%

6 Months

-32.76%

1 Year

-82.77%

2 Years

-87.16%

3 Years

-89.56%

4 Years

-95.04%

5 Years

-97.56%

Pulmonx Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

22.48%

EBIT Growth (5y)

-162.69%

EBIT to Interest (avg)

-28.26

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.65

Sales to Capital Employed (avg)

0.60

Tax Ratio

0.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.13

EV to EBIT

-0.52

EV to EBITDA

-0.53

EV to Capital Employed

1.37

EV to Sales

0.32

PEG Ratio

Dividend Yield

ROCE (Latest)

-266.08%

ROE (Latest)

-94.54%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (38.93%)

Foreign Institutions

Held by 66 Foreign Institutions (14.27%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -5.04% vs 23.32% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 21.21% vs 5.04% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22.60",
          "val2": "23.80",
          "chgp": "-5.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.70",
          "val2": "-13.10",
          "chgp": "25.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.40",
          "val2": "-13.20",
          "chgp": "21.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-438.20%",
          "val2": "-564.60%",
          "chgp": "12.64%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.00% vs 21.98% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 4.26% vs 7.24% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "90.50",
          "val2": "83.80",
          "chgp": "8.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-52.50",
          "val2": "-54.40",
          "chgp": "3.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.20",
          "val2": "3.50",
          "chgp": "-8.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.00",
          "val2": "-56.40",
          "chgp": "4.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-593.00%",
          "val2": "-668.20%",
          "chgp": "7.52%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

22.60

23.80

-5.04%

Operating Profit (PBDIT) excl Other Income

-9.70

-13.10

25.95%

Interest

0.80

Exceptional Items

0.00

Consolidate Net Profit

-10.40

-13.20

21.21%

Operating Profit Margin (Excl OI)

-438.20%

-564.60%

12.64%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is -5.04% vs 23.32% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 21.21% vs 5.04% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

90.50

83.80

8.00%

Operating Profit (PBDIT) excl Other Income

-52.50

-54.40

3.49%

Interest

3.20

3.50

-8.57%

Exceptional Items

0.00

-1.70

100.00%

Consolidate Net Profit

-54.00

-56.40

4.26%

Operating Profit Margin (Excl OI)

-593.00%

-668.20%

7.52%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 8.00% vs 21.98% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 4.26% vs 7.24% in Dec 2024

All Annual Results

Company CV

About Pulmonx Corp.

Pulmonx Corp.

Pharmaceuticals & Biotechnology

Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

Company Coordinates

Company Details

700 Chesapeake Dr , REDWOOD CITY CA : 94063

Tel: 1 650 3640400

Registrar Details